New Protocol: Belzutifan and Cabozantinib for Advanced RCC

  • Study

    Phase II, single-arm, open-label, multicenter study
    Locally advanced or metastatic clear cell renal cell carcinoma had previously received immunotherapy and up to two systemic treatment regimens.
    Belzutifan + Cabozantinib (n=52)


  • Efficacy

    cORR: 30.8% [16 of 52 pts]
    CR: 2.0% [1 of 52 pts]
    PR: 29% [15 of 52 pts]

  • Safety

    Grade3: Hypertension (27%)1 pts death from treatment related respirator failure



    • Lancet Oncol, VOLUME 24, ISSUE 5, P553-562, MAY 2023

    Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study

    http://doi.org/10.1016/S1470-2045(23)00097-9

    Reviewed by Elvin Chalabiyev, MD on Jun 24, 2023

    Altai Oncology App
    Download Altai Oncology App On App Store
    Download Altai Oncology App On Play Store
    • Chemotherapy Protocols
    • Summarized References
    • Oncology Drug Specs
    • TNM Staging
    • BSA, CrCl Calculator
    Back to top Drag